Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.56 |
| ▸ | GSK3B | P49841 | 5/20 | 0.50 |
| ▸ | CLK1 | P49759 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 10/20 | 0.49 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957480 | 1.00 | DYRK1A (0.56) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL4491392 | 0.86 | DYRK1A (0.75) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL17542614 | 0.83 | AR (0.62) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL19100699 | 0.83 | CDK5 (0.71) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL30957630 | 0.83 | AR (0.62) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL18662633 | 0.83 | DYRK1A (0.64) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL24900746 | 0.80 | DYRK1A (0.73) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL30436509 | 0.80 | DYRK1A (0.73) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL19100649 | 0.80 | DYRK1A (0.53) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL21870744 | 0.80 | DYRK1A (0.51) | DYRK1AGSK3BCLK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-118159533-A | Heterocyclic compounds and their use | 艾森医药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4370212-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-113121575-A | (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| CN-102267988-A | 2-aminopyrimidine derivatives and their medical use | NOVARTIS LTD | 2011-12-07 | — | — | CN | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1802357-A | 2-aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2006-07-12 | — | — | CN | disclosed |
| EP-1615898-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | Novartis AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | DYRK1A 1869/4885GSK3B 906/4885CLK1 2915/4885 |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | DYRK1A 3619/4885GSK3B 352/4885CLK1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.